
Saturday, November 09, 2024 10:35:53 PM
Kevin Tseng
From:kevin-tseng@prismabiotech.com.tw
To:XXXXX XXXXXXX
Fri, Jul 19 at 6:27 AM
Hi XXXXXXXX
Thanks for your interest in our stock.
We have used our proprietary technology called HIPNA to develop a kind of multi-functional hydrogel material AQUIPHER which can be applied to a variety of market segments, including wound care, skin care and transdermal drug delivery. We are preparing to launch our first stage of products before end of this year. With several leading features, we believe our products can attract the industry’s attention and have strong potential to grow revenues in north American market.
With all the best,
Kevin Tseng.
We shall see.
VAYK Corrects Major Clerical Error to Report $668K Operating Revenue for 2024 • VAYK • Apr 17, 2025 9:00 AM
UAV Corp Names David Dugas as President and Chief Operating Officer • UMAV • Apr 17, 2025 8:30 AM
Yuengling's Ice Cream Corporation (OTC: YCRM), Doing Business as ReachOut, Files 2024 10-K With Profitability, Growth, and Corporate Transformation in Focus • YCRM • Apr 16, 2025 11:07 AM
Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit • AVAI • Apr 16, 2025 8:00 AM
HealthLynked Welcomes Anthony Scuilla as Sales Consultant to Drive Strategic Partnerships with Insurance Providers • HLYK • Apr 14, 2025 8:00 AM
Glidelogic Corp. Partners with Sunwah Global Youth Innovation Center • GDLG • Apr 10, 2025 4:00 PM